Jankowski, T., Csoszi, T., Urban, L., Nagy, T., Ramlau, R., Cholakova, M., Chilingirova, N., Mruk, A., Soter, S., Koynov, K. D., Kotlarski, M., Girotti, R., Mender, I., Mitsunaga, M., Tudos, O., Failor, M., Yao, B., Vitoc, V., Gryaznov, S., Zaporojan, V. (2025). Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8585